Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.

被引：13

作者：

Coward, Jermaine

Mislang, Anna Rachelle Austria

Frentzas, Sophia

Lemech, Charlotte Rose

Nagrial, Adnan

Jin, Xiaoping

Li, Baiyong

Wang, Zhongmin Maxwell

Kwek, Kon Yew

Xia, Yu

机构：

[1] ICON Canc Care, South Brisbane, Qld, Australia

[2] Adelaide Canc Ctr, Kurralta Pk, SA, Australia

[3] Monash Hlth, Melbourne, Vic, Australia

[4] Scientia Clin Res, Randwick, NSW, Australia

[5] Blacktown Hosp Canc & Haematol Ctr, Blacktown, NSW, Australia

[6] Akeso Biopharma Inc, Zhongshan, Peoples R China

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.2515

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2515

引用

页数：2